CT-P6 SC (trastuzumab SC biosimilar) / Celltrion - LARVOL DELTA

To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab) (clinicaltrials.gov) - P1 | N=200 | Active, not recruiting | Sponsor: Celltrion | Recruiting ➔ Active, not recruiting

Enrollment closed

Celltrion expands subcutaneous pipeline as Herzuma SC heads to trial (Korea Biomedical Review) - "On Thursday, the Ministry of Food and Drug Safety (MFDS) greenlit a phase 1 clinical trial for CT-P6 SC, Celltrion’s SC version of Herzuma, its biosimilar to Roche’s Herceptin (trastuzumab). The trial will compare the pharmacokinetics, safety, and immunogenicity of CT-P6 SC against Genentech’s Herceptin Hylecta, which combines trastuzumab with recombinant human hyaluronidase to enable subcutaneous injection."

New P1 trial • Oncology